Multimodal intervention

Multimodal intervention has been studied in 24 papers since 2016: 11 trials in people, 2 in animals, 7 reviews; 7 in the past year. The newest paper, Nov 6, 2026: “A Multimodal Intervention Including Tirzepatide in Women with Lipedema and Excess Body Weight: A Pilot Case Series”.

Intervention

24 papers study it41 findingsUpdated

1 new paper in 30 daysSee all 24 papers on multimodal intervention

At a glance

Multimodal interventions improve physical function and quality of life in human trials, with independent labs finding these changes again. A trial in frail and prefrail older people with type 2 diabetes finds no clear mortality effect; another reports more serious adverse events. Some authors are affiliated with Ingenasa.

41 findings in 16 papers from 2017 to 2026, 2 of them since May 2026

Independent labs found the same change in people. 16 independent labs in 15 countries.

“IG participants had mean SPPB scores 0.85 points higher than those in the UCG (95% CI, 0.44 to 1.26, P < 0.0001)”
Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitusJournal of cachexia, sarcopenia and muscle2019doi:10.1002/jcsm.12432

None of its findings points the other way.

Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
  • 16 independent labs in 15 countries
  • Funders: University of Zaragoza and others
  • 5 of 41 findings with company ties
  • Human trial11
  • Animals2

10 studies gave multimodal intervention to people and measured what changed.

What changedDesignPeopleSource

down: Decreases body weightWeight loss ranged from 7.7 to 17.1 kg

down: Decreases lower-limb circumferences and subcutaneous adipose tissue thickness

down: Decreases fasting glucoseDecreased in most cases

Treated cohort22–25 weeks5 peopleWomenLipedema and excess body weight; tirzepatide included in four participantsJournal of clinical medicine, Nov 6, 2026

up: Improves mobilityβ = -0.30, p < .05

up: Improves activities of daily livingβ = -8.40, p < .01

Randomized trialsix months post-discharge589 people52% male79.57 ± 5.44 yearsGeriatric patients aged 70 years or older in an acute hospital setting with increased risk for delirium, mobility restrictions, functional decline, or re-hospitalizationAging clinical and experimental research, Mar 8, 2026

no change: Has no effect on gait performance

Randomized trial12 weeks12 people72.6 ± 5.4 yearsOlder adultsBMC geriatrics, Nov 4, 2025

up: Improves quality of lifeOR 1.75 (95% CI 1.20, 2.54), p=0.004

down: Decreases disabilityOR 0.59 (95% CI 0.37, 0.93), p=0.023

Randomized trial16 weeks843 peopleBoth≥ 70 yearsOlder adults; prefrail and frail with type 2 diabetes mellitusDiabetes research and clinical practice, Jul 27, 2024

up: Raises the risk of serious adverse events+365% relative risk

Review of trialsmedian study duration for all studies was 6 months, with the shortest intervention period lasting 2 h (0.00274 months) and the longest intervention lasting 10 years (120 months)minimum age of 60 yearsParticipants in U.S.-based lifestyle clinical trials for cognitive healthContemporary clinical trials communications, Feb 15, 2024

What did studies of multimodal intervention find?

33

Studies of multimodal intervention measured 33 outcomes, among them inflammation, quality of life and physical function.

Inflammation

downin humans1downin mice1

2 studies
  1. Multimodal intervention decreases inflammation in humans.

    Human trialthree monthsfemales

  2. Multimodal intervention decreases inflammation in AD mice.

    Animalsin AD mice

More on Inflammation

Quality of life

upin humans2OR 1.75

2 studies
  1. Multimodal intervention improves quality of life in humans (β = 2.43, 95% CI [1.50, 3.35]).

    Human trial18 months

  2. Multimodal intervention improves quality of life in humans (prefrail and frail with type 2 diabetes mellitus) (OR 1.75 (95% CI 1.20, 2.54), p=0.004).

    Human trialprefrail and frail with type 2 diabetes mellitus16 weeksn = 843

Physical function

upin humans2

2 studies
  1. Multimodal intervention improves physical function in humans (frail and pre-frail older people with type 2 diabetes mellitus) (0.85 points (95% CI, 0.44 to 1.26, P < 0.0001)).

    Human trialfrail and pre-frail older people with type 2 diabetes mellitus12 monthsn = 964

  2. Multimodal intervention improves physical function in humans during and immediate post-treatment.

    Reviewduring and immediate post-treatment

Health care costs

downin humans2

2 studies
  1. Multimodal intervention decreases health care costs in humans (frail and pre-frail people with type 2 diabetes, compared with usual care) (25% lower than usual care).

    Human trialfrail and pre-frail people with type 2 diabetes, compared with usual careone year

  2. Multimodal intervention decreases health care costs in humans (frail and pre-frail older people with type 2 diabetes mellitus) (mean saving of 428.02 EUR (2016) per patient per year).

    Human trialfrail and pre-frail older people with type 2 diabetes mellitus12 months

Activities of daily living

upin humans1

1 study
  1. Multimodal intervention improves activities of daily living in humans (β = -8.40, p < .01).

    Human trialn = 589

  2. Multimodal intervention improves activities of daily living in humans (hospitalized geriatric patients) (β = 7.98, p<.001).

    Human trialhospitalized geriatric patientssix months post-dischargen = 589

Mobility

upin humans1

1 study
  1. Multimodal intervention improves mobility in humans (β = -0.30, p < .05).

    Human trialn = 589

  2. Multimodal intervention improves mobility in humans (hospitalized geriatric patients) (β = 0.70, p<.001).

    Human trialhospitalized geriatric patientssix months post-dischargen = 589

Physical activity

upin humans1

1 study
  1. Multimodal intervention increases physical activity in humans.

    Human trial8 weeks

  2. Multimodal intervention increases physical activity in humans (P value <0.05).

    Human trial8 weeks

SF-36 scores

upin humans1

1 study
  1. Multimodal intervention improves SF-36 scores in humans (tirzepatide phase with concurrent dietary, exercise, and supplementation interventions).

    Human trialtirzepatide phase with concurrent dietary, exercise, and supplementation interventionstirzepatide 2.5–7.5 mg once weekly14–16 weeksfemalesn = 4

Fasting glucose

downin humans1

1 study
  1. Multimodal intervention decreases fasting glucose in humans (lipedema and excess body weight) (Decreased in most cases).

    Human triallipedema and excess body weight22–25 weeksfemalesn = 5

More on Fasting glucose

Lower-limb circumferences and subcutaneous adipose tissue thickness

downin humans1

1 study
  1. Multimodal intervention decreases lower-limb circumferences and subcutaneous adipose tissue thickness in humans (lipedema and excess body weight).

    Human triallipedema and excess body weightlower-limb subcutaneous adipose tissue22–25 weeksfemalesn = 5

Body weight

downin humans1

1 study
  1. Multimodal intervention decreases body weight in humans (lipedema and excess body weight; tirzepatide included in four participants) (Weight loss ranged from 7.7 to 17.1 kg).

    Human triallipedema and excess body weight; tirzepatide included in four participants22–25 weeksfemalesn = 5

Balance

no changein humans1

1 study
  1. Multimodal intervention showed no clear effect on balance in humans (β = 0.10, 95% CI [− 0.38, 0.58]).

    Human trial18 months

Loneliness

downin humans1

1 study
  1. Multimodal intervention decreases loneliness in humans (β = −1.25, 95% CI [− 1.99, − 0.52]).

    Human trial18 months

Depression

downin humans1

1 study
  1. Multimodal intervention decreases depression in humans (β = −1.32, 95% CI [− 1.81, − 0.82]).

    Human trial18 months

Cognitive function

upin humans1

1 study
  1. Multimodal intervention improves cognitive function in humans (β = 1.07, 95% CI [0.45, 1.70]).

    Human trial18 months

All 33

What is multimodal intervention linked with?

1

Studies link multimodal intervention with serious adverse events.

Serious adverse events

upin humans1+365% relative risk

1 study
  1. Multimodal intervention raises the risk of serious adverse events in humans (+365% relative risk).

    Human trialmedian study duration for all studies was 6 months, with the shortest intervention period lasting 2 h (0.00274 months) and the longest intervention lasting 10 years (120 months)

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 4Apr 2026: 0May 2026: 2Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 17 papers in 12 months

See all 24 papers on multimodal intervention